|Bid||230.00 x 100|
|Ask||247.90 x 100|
|Day's Range||246.21 - 249.21|
|52 Week Range||184.50 - 261.27|
|PE Ratio (TTM)||7.69|
|Dividend & Yield||2.80 (1.12%)|
|1y Target Est||N/A|
Sarepta Therapeutics Inc said on Wednesday it appointed Douglas Ingram as president and chief executive officer. Ingram, who previously held a senior executive position in Allergan Plc, will also be a ...
While the Republican-led Congress continues the push to repeal the Affordable Care Act, we still see challenges in passing any new legislation.
Shares of Valeant Pharmaceuticals International (VRX) spiked yesterday on speculation regarding a possible debt-to-equity swap by the troubled drug maker. Wells Fargo analyst David Maris weighed in on the notion today, arguing that even if a swap does happen, it does not repair poor business trends or the increasingly unlikelihood that Valeant can deliver the strong earnings growth promised by consensus forecasts. As Maris writes: Based on our experience and feedback from our high yield debt analyst, we think that most debt holders do not have the ability or interest to take cross structure risk.